Abstract:Checkpoint inhibitors have been very successful in various tumors, including melanoma and lung cancer. However, these treatments have failed in other tumors, including pancreatic cancer and glioblastoma. Approaches harnessing the immune response are hindered by multiple factors, including T cell exhaustion. Exhausted T cells are less capable of limiting tumor progression. TOX is particularly important for the transcriptional and epigenetic reprogramming of exhausted T cells, and without TOX, T cells cannot differentiate down the exhaustion pathway. While it is known that NFAT is directly upstream of TOX, our understanding of the pathways that lead to the upregulation of TOX remains incomplete. We hypothesized that tumor necrosis factor (TNF) could be involved in the upregulation of TOX, as TNF has been shown to induce exhaustion and can lead to the translocation of NFAT into the nucleus. While we did not detect an upregulation of the pro-inflammatory TNF receptor type I (TNFR1), we observed significant upregulation of the anti-inflammatory TNF receptor type II (TNFR2) in tumor-infiltrating T cells, but not in lymphoid organs. This local upregulation mimics expression patterns of canonical exhaustion markers and suggests that TNFR2 signaling could be involved in the progression of exhaustion. In support of this hypothesis, TNFR2 expression is correlated other markers of exhaustion, including PD1, TIM3, and TOX. Furthermore, TNFR2 knock out (KO) CD8 T cells have significantly lower expression of TOX, without the concomitant decrease of TIM3. Whereas previous studies have intricately linked TIM3 and TOX expression, these data suggest that TIM3 and TOX are regulated independently. To further evaluate transcriptional regulation of WT and KO T cells, we utilized bulk RNA-sequencing. After performing pathway analyses, we detected a significant reduction of T cell exhaustion, senescence, and immune checkpoint pathways in TNFR2 KO T cells. We identified significant decreases in various exhaustion-related transcription factors and coinhibitory markers. In contrast, we discovered a significant increase in AP1 transcription factors, commonly associated with T cell effector functions. Given this reduced exhaustion profile, we subsequently investigated the influence of TNFR2 on tumor burden. TNFR2 KO mice had significantly less tumor burden following subcutaneous tumor challenges. To make this approach more translatable, we treated mice with a TNFR2 antagonist. While the antagonist alone was not sufficient to improve tumor control, combination with immune checkpoint blockade (anti-PD1) significantly reduced tumor volumes in traditionally resistant models. These data provide evidence for a novel marker of exhaustion that could result in a novel therapeutic strategy. Citation Format: Alexandra Hoyt-Miggelbrink, Jessica Waibl Polania, Aditya Mohan, Luke Wachsmuth, Selena Lorrey, Emily Lerner, Daniel Wilkinson, Andrew Hardigan, Kelly Hotchkiss, Saskia Hemmers, Sarah Cook Quackenbush, Katayoun Ayasoufi, Peter Fecci. TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A056.

The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma

TOX is a critical regulator of tumour-specific T cell differentiation

Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer

Increased TOX Expression Concurrent with PD-1, Tim-3, and CD244 in T Cells from Patients with Non-Hodgkin Lymphoma.

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Exhausted T cells and epigenetic status

Increased TOX Expression Concurrent with PD-1, Tim-3, and CD244 Expression in T Cells from Patients with Acute Myeloid Leukemia.

Increased TOX Expression Associates with Exhausted T Cells in Patients with Multiple Myeloma

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Transcription factor TOX maintains the expression of Mst1 in controlling the early mouse NK cell development

Higher TOX Genes Expression is Associated with Poor Overall Survival for Patients with Acute Myeloid Leukemia.

TNFR2 loss leads to decreased TOX expression in T cells without affecting TIM3 and improves responses to tumor and chronic LCMV

TOX Promotes the Exhaustion of Antitumor CD8(+) T Cells by Preventing PD1 Degradation in Hepatocellular Carcinoma

Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection

Immu-05. Tnfr2 Is A Novel Marker Of Exhaustion And Tnfr2 Blockade Improves Subcutaneous Tumor Control

Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade

Abstract A056: TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control

T-cell Exhaustion Interrelates with Immune Cytolytic Activity to Shape the Inflamed Tumor Microenvironment.

Depletion of Foxp3+ regulatory T cells but not the absence of CD19+IL‐10+ regulatory B cells hinders tumor growth in a para‐orthotopic neuroblastoma mouse model

Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction

Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways